Cell Therapy Gets Official Green Light For Use In Russia

TASS – December 31, 2016: The law Putin sign on biomedical cellular products will come into force on January 1, 2017, permiting the use of living cells for therapy and kicks off the creation of a new branch of biomedicine.

The law on biomedical cellular products which comes into force on January 1 permits the use of living cells for therapy and kicks off the creation of a new branch of biomedicine, one of the law’s authors, Andrei Vasilyev, Director of the Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, told TASS.

“The law will boost the development of biomedical research and the new high-tech industry but, most importantly, patients will be able to receive highly effective treatment with the use of artificially grown cells, the quality and safety of which will be guaranteed by the government,” said Andrei Vasilyev, the head of the RAS Institute of Developmental Biology.

In contrast with transplantation, the patient’s body does not reject cellular material.

“This is a very important law for researchers, medics and patients as the development of biomedicine and cellular technologies has been legalized for the very first time in Russia,” Deputy Education and Science Minister Sergei Krayevoi stressed. “This is a new step towards the development of contemporary methods of treatment for serious diseases.”

Biomedical cellular products basically differ from pharmaceutical drugs and medical devices.

According to Vasilyev, a millimeter-piece of biomaterial is taken from the donor’s body to produce biomedical cellular products.

“Then the cells are scaled up, modified and combined with some medicines and as a result we get a new biomedical cellular product,” the scientist explained. “Contemporary technologies facilitate the production of neurons or heart cells from a small skin sample. The possibilities here become endless.”

Biomedical cellular products can be used for treatment of cancer, diabetes, liver, heart and other diseases. Link: Read Complete Article

END